HOME >> BIOLOGY >> NEWS
Rethinking anti-oxidants

A leading researcher at the University of New South Wales (UNSW) points out that there is little convincing evidence that dietary antioxidant supplements such as vitamin E prevent heart disease, despite claims to the contrary.

Instead there has been a surprise finding, which relates to a synthetic antioxidant, the drug Probucol, which is no longer prescribed in Australia.

"There has been a lot of hype which suggested that antioxidant vitamin supplements had a beneficial outcome for cardiovascular disease. There is no good scientific support for the notion that people who suffer from atherosclerosis, or who are at elevated risk of heart disease, gain benefit by supplements of vitamin E," said Professor Roland Stocker, from the Centre for Vascular Research at UNSW, who will present his research at the ISTH Congress in Sydney today.

Stocker reported, "Our research is now leading towards the development of a new drug, based on Probucol. Probucol was previously used to reduce so-called "bad" cholesterol for those with heart disease, but it also had side effects, such as reducing "good" cholesterol and possibly inducing an irregular heartbeat.

This new compound, which has a similar structure to probucol, is very effective in protecting against atherosclerosis (the principal cause of coronary heart disease) in animal models but doesn't have the same side effects"

He went onto say, "We have shown that this novel probucol-analog induces a pathway in the vessel wall which is both anti-oxidative and anti-inflammatory. The early signs are that it provides strong protection for blood vessel walls. We are now progressing these studies further with a pharmaceutical company."

"This compound potentially represents a new approach for treating people with or at risk of heart disease at the source of the problem in the vessel wall. Vitamin E is not depleted or deficient in people with heart disease. It is in my view, a nave ide
'"/>

Contact: Sarah Meachem
Sarah.Meachem@phimr.monash.edu.au
61-412-640-774
Research Australia
9-Aug-2005


Page: 1 2

Related biology news :

1. Rethinking new therapies for Crohns disease at U.Va.

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer ... hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. ... development activities. , “Dr. Floyd’s career has spanned 30 years in the chemicals ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... Ca (PRWEB) , ... March 21, 2017 , ... ... clearance of biologics. To acquire information on the desired increase and/or decrease in ... biopharmaceutical industry for rapid N-glycosylation profiling of therapeutic antibodies. , To meet ...
Breaking Biology Technology:
Cached News: